The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis

被引：35

作者：

Li, Xiaobo ^{[1
,2
]}

Li, Yong ^{[1
,2
]}

Lu, Weijin ^{[1
,2
]}

Chen, Minfeng ^{[1
,2
]}

Ye, Wencai ^{[1
,2
]}

Zhang, Dongmei ^{[1
,2
]}

机构：

[1] Jinan Univ, Coll Pharm, 601 Huangpu Rd West, Guangzhou 510632, Peoples R China

[2] Jinan Univ, Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou 510632, Peoples R China

来源：

CELLS | 2019年 / 8卷 / 12期

基金：

中国国家自然科学基金;

关键词：

tumor metastasis; angiogenesis; vessel targeting drugs; pro-metastasis risk; ANTI-ANGIOGENIC THERAPY; RENAL-CELL CARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION; ANTIANGIOGENIC THERAPY; LUNG METASTASIS; PHASE-III; CO-OPTION; VASCULAR NORMALIZATION; MEDIATES RESISTANCE; CANCER METASTASIS;

D O I：

10.3390/cells8121602

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Tumor vessels provide essential paths for tumor cells to escape from the primary tumor and form metastatic foci in distant organs. The vessel targeting strategy has been widely used as an important clinical cancer chemotherapeutic strategy for patients with metastatic tumors. Our review introduces the contribution of angiogenesis to tumor metastasis and summarizes the application of Food and Drug Administration (FDA)-approved vessel targeting drugs for metastatic tumors. We recommend the application and mechanisms of vascular targeting drugs for inhibiting tumor metastasis and discuss the risk and corresponding countermeasures after vessel targeting treatment.

引用

页数：21

共 156 条

[1] Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer [J].

Achyut, Bhagelu R. ;

Arbab, Ali S. .

ONCOTARGETS AND THERAPY, 2016, 9 :1047-1055

[2] Fibroblast-derived CXCL12 promotes breast cancer metastasis by facilitating tumor cell intravasation [J].

Ahirwar, Dinesh K. ;

Nasser, Mohd W. ;

Ouseph, Madhu M. ;

Elbaz, Mohamad ;

Cuitino, Maria C. ;

Kladney, Raleigh D. ;

Varikuti, Sanjay ;

Kaul, Kirti ;

Satoskar, Abhay R. ;

Ramaswamy, Bhuvaneswari ;

Zhang, Xiaoli ;

Ostrowski, Michael C. ;

Leone, Gustavo ;

Ganju, Ramesh K. .

ONCOGENE, 2018, 37 (32) :4428-4442

[3] Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review [J].

Al-Abd, Ahmed M. ;

Alamoudi, Abdulmohsin J. ;

Abdel-Naim, Ashraf B. ;

Neamatallah, Thikryat A. ;

Ashour, Osama M. .

JOURNAL OF ADVANCED RESEARCH, 2017, 8 (06) :591-605

[4] Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation [J].

Allen, Elizabeth ;

Jabouille, Arnaud ;

Rivera, Lee B. ;

Lodewijckx, Inge ;

Missiaen, Rindert ;

Steri, Veronica ;

Feyen, Kevin ;

Tawney, Jaime ;

Hanahan, Douglas ;

Michael, Iacovos P. ;

Bergers, Gabriele .

SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (385)

[5] Ramucirumab: preclinical research and clinical development [J].

Aprile, Giuseppe ;

Rijavec, Erika ;

Fontanella, Caterina ;

Rihawi, Karim ;

Grossi, Francesco .

ONCOTARGETS AND THERAPY, 2014, 7 :1997-2006

[6] Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake [J].

Arjaans, Marlous ;

Munnink, Thijs H. Oude ;

Oosting, Sjoukje F. ;

van Scheltinga, Anton G. T. Terwisscha ;

Gietema, Jourik A. ;

Garbacik, Erik T. ;

Timmer-Bosscha, Hetty ;

Lub-de Hooge, Marjolijn N. ;

Schroder, Carolina P. ;

de Vries, Elisabeth G. E. .

CANCER RESEARCH, 2013, 73 (11) :3347-3355

[7] Ramucirumab in the treatment of non-small cell lung cancer [J].

Arrieta, Oscar ;

Lucia Zatarain-Barron, Zyanya ;

Cardona, Andres F. ;

Carmona, Amir ;

Lopez-Mejia, Mariana .

EXPERT OPINION ON DRUG SAFETY, 2017, 16 (05) :637-644

[8] Tumor-Recruited Neutrophils and Neutrophil TIMP-Free MMP-9 Regulate Coordinately the Levels of Tumor Angiogenesis and Efficiency of Malignant Cell Intravasation [J].

Bekes, Erin M. ;

Schweighofer, Bernhard ;

Kupriyanova, Tatyana A. ;

Zajac, Ewa ;

Ardi, Veronica C. ;

Quigley, James P. ;

Deryugina, Elena I. .

AMERICAN JOURNAL OF PATHOLOGY, 2011, 179 (03) :1455-1470

[9] Tyrosine kinase receptors as attractive targets of cancer therapy [J].

Bennasroune, A ;

Gardin, A ;

Aunis, D ;

Crémel, G ;

Hubert, P .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (01) :23-38

[10] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].

Bennouna, Jaafar ;

Sastre, Javier ;

Arnold, Dirk ;

Osterlund, Pia ;

Greil, Richard ;

Van Cutsem, Eric ;

von Moos, Roger ;

Maria Vieitez, Jose ;

Bouche, Olivier ;

Borg, Christophe ;

Steffens, Claus-Christoph ;

Alonso-Orduna, Vicente ;

Schlichting, Christoph ;

Reyes-Rivera, Irmarie ;

Bendahmane, Belguendouz ;

Andre, Thierry ;

Kubicka, Stefan .

LANCET ONCOLOGY, 2013, 14 (01) :29-37

← 1 2 3 4 5 6 7 8 9 10 →